Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 11 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
Miltenyi Biotec B.V. & Co. KG has 12 pending office actions in Biotechnology & Pharmaceuticals. Each matter is associated with a distinct examiner and a distinct art unit, for 12 distinct examiners and 12 distinct art units. NGUYEN, THONG Q is the busiest examiner, with 1 pending matter.
The one-to-one distribution requires a portfolio process that preserves application-level control while maintaining consistent biotechnology and pharmaceutical terminology. Counsel should not rely on a repeated examiner approach, because the data shows separate examination channels for the pending matters. Centralized review can still identify common specification-support issues, claim structures, or technical explanations before each response is tailored to its individual record.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (27%) |
| §112 only | 2 (18%) |
| Double-patenting + other | 1 (9%) |
| Multi-statute (no §101) | 5 (45%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, THONG Q | 1 | 67.8% | +12.0% |
| RAHMAN, MASUDUR | 1 | 72.9% | +31.7% |
| GAO, ASHLEY HARTMAN | 1 | 56.5% | +38.0% |
| OGUNTADE, ELIZABETH BISOLA | 1 | 50.0% | +100.0% |
| PHAM, KHAI QUYNH TIEN | 1 | 0.0% | +0.0% |
| BUNNER, BRIDGET E | 1 | 64.6% | +19.8% |
| GREENE, CAROLYN LEE | 1 | 65.7% | +46.1% |
| DU, SURBHI M | 1 | 66.9% | +29.1% |
| DIBRINO, MARIANNE | 1 | 42.8% | +42.2% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280706 | ARTIFICIAL TARGET FOR ANTIGEN-SPECIFIC ACTIVATION AND EXPANSION OF CAR T CELLS | OGUNTADE, ELIZABETH BISOLA | 9d |
| 18701572 | Method for the generation of genetically modified NK cells | RAHMAN, MASUDUR | — |
| 18274541 | Method for Library Preparation in Next Generation Sequencing by Enzymatic DNA Fragmentation | PHAM, KHAI QUYNH TIEN | — |
| 18035356 | Methods and compositions for eliminating engineered immune cells | BUNNER, BRIDGET E | — |
| 17797419 | Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens | DIBRINO, MARIANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280706 | ARTIFICIAL TARGET FOR ANTIGEN-SPECIFIC ACTIVATION AND EXPANSION OF CAR T CELLS | OGUNTADE, ELIZABETH BISOLA | 9d |
| 18657878 | METHOD AND APPARATUS FOR HIGH RESOLUTION MICROSCOPY | NGUYEN, THONG Q | — |
| 18701572 | Method for the generation of genetically modified NK cells | RAHMAN, MASUDUR | — |
| 18369273 | BIOLOGICAL CONJUGATES HAVING AN PHOTOGENERATED ACIDIC OR BASIC RELEASABLE DETECTION MOIETY ON TOP OF BIOLOGICAL TISSUES | GAO, ASHLEY HARTMAN | — |
| 18035356 | Methods and compositions for eliminating engineered immune cells | BUNNER, BRIDGET E | — |
| 18307406 | EX-SITU SEQUENCING OF RCA PRODUCT GENERATED IN-SITU | GREENE, CAROLYN LEE | — |
| 18015351 | FLUORESCENT DYES COMPRISING M-CONJUGATED 1,1 -BINAPHTHYL-BASED POLYMERS | DU, SURBHI M | — |
| 17797419 | Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens | DIBRINO, MARIANNE | — |
| Art Unit | Apps |
|---|---|
| 2872 | 1 |
| 1633 | 1 |
| 1678 | 1 |
| 1677 | 1 |
| 1684 | 1 |
| 1647 | 1 |
| 1681 | 1 |
| 1765 | 1 |
| 1641 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18657878 | METHOD AND APPARATUS FOR HIGH RESOLUTION MICROSCOPY | NGUYEN, THONG Q | 2872 | §112 | Non-Final OA | — | Pending | May 08, 2024 |
| 18701572 | Method for the generation of genetically modified NK cells | RAHMAN, MASUDUR | 1633 | §102§103 | Non-Final OA | — | Pending | Apr 15, 2024 |
| 18369273 | BIOLOGICAL CONJUGATES HAVING AN PHOTOGENERATED ACIDIC OR BASIC RELEASABLE DETECTION MOIETY ON TOP OF BIOLOGICAL TISSUES | GAO, ASHLEY HARTMAN | 1678 | §103DP | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18280706 | ARTIFICIAL TARGET FOR ANTIGEN-SPECIFIC ACTIVATION AND EXPANSION OF CAR T CELLS | OGUNTADE, ELIZABETH BISOLA | 1677 | §103§112 | Non-Final OA | 9d | Pending | Sep 07, 2023 |
| 18274541 | Method for Library Preparation in Next Generation Sequencing by Enzymatic DNA Fragmentation | PHAM, KHAI QUYNH TIEN | 1684 | §103§112 | Final Rejection | — | Pending | Jul 27, 2023 |
| 18035356 | Methods and compositions for eliminating engineered immune cells | BUNNER, BRIDGET E | 1647 | §103§112 | Non-Final OA | — | Pending | May 04, 2023 |
| 18307406 | EX-SITU SEQUENCING OF RCA PRODUCT GENERATED IN-SITU | GREENE, CAROLYN LEE | 1681 | §112 | Final Rejection | — | Pending | Apr 26, 2023 |
| 18015351 | FLUORESCENT DYES COMPRISING M-CONJUGATED 1,1 -BINAPHTHYL-BASED POLYMERS | DU, SURBHI M | 1765 | §103Other | Final Rejection | — | Pending | Jan 10, 2023 |
| 17797419 | Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens | DIBRINO, MARIANNE | 1641 | §102§112 | Non-Final OA | — | Pending | Aug 03, 2022 |
| 17612410 | Method for Generation of Genetically Modified T Cells | ALAM, DANYAL HASSAN | 1672 | §103 | Non-Final OA | — | Pending | Nov 18, 2021 |
| 16622825 | METHODS FOR PURIFYING ENDODERM AND PANCREATIC ENDODERM CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS | GONZALES, JOSEPHINE MARIA | 1631 | §103 | Non-Final OA | — | Pending | Dec 13, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMiltenyi Biotec B.V. & Co. KG has 11 pending office actions as of October 2026, spread across 11 art units and 11 examiners.
Thong Q Nguyen has the most, with 1 of Miltenyi Biotec B.V. & Co. KG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
